ClinicalTrials.gg
Active, not recruitingNCT04417621Updated Mar 12, 2026

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

A Phase 2 interventional study of LXH254 and LTT462 in Melanoma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 36 sites in 12 countries. Open to participants aged 12 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

How we know · 10 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
12 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing trametinib in Melanoma — 2 open to participants now, 10 under way, none of them phase 3. trametinib · Melanoma.

Enrollment
10th of 46
134 · median 47
Started
2020
the only one that year
Phase 2
25 of 46
1 open now
Registered
44th of 46
by date
Lead sponsor
8 of 46
Novartis Pharmaceuticals

Among the 46 studies testing trametinib in Melanoma, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 25 in phase 2, and was the 44th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 46 studies testing trametinib in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About trametinib

trametinib: first FDA approval 2013 (MEKINIST), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing trametinib in Melanoma, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • LXH254
  • Melanoma
  • NRAS
  • BRAF
  • LTT462
  • Trametinib
  • Ribocliclib
04

Who can participate

Ages eligible
12 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female must be ≥ 12 years For adolescents only (12-17 years): body weight > 40kg confirmed unresectable or cutaneous melanoma

Previously treated for unresectable or metastatic melanoma:

  • Participants with NRAS mutation:
  • Participants must have received prior systemic therapy for unresectable or metastatic melanoma with (CPI), either an anti-PD-1/PD-L1 as a single agent or in combination with anti-CTLA-4, agents, chemotherapy or locally directed anti-neoplastic agents.
  • A maximum of two prior lines of systemic CPI-containing immunotherapy for unresectable or metastatic melanoma are allowed. Additional agents administered with CPI are permitted.
  • To rule out pseudo-progression, participants must have documented confirmed progressive disease as per v1.1 while on/after treatment with checkpoint inhibitor therapy. Confirmation is not required for patients who remained on treatment for >6 months.
  • Participants with BRAFV600 mutant disease:
  • Participants must have received prior systemic therapy for unresectable or metastatic melanoma with checkpoint inhibitors (CPI), either an anti-PD-1/PD-L1 as a single agent or in combination with anti-CTLA-4, investigational agents, chemotherapy or locally directed anti-neoplastic agents. Additionally, participants must have received targeted therapy with a RAFi as a single agent or in combination with a MEKi (+/- CPI allowed) as the last prior therapy.
  • A maximum of two prior lines of systemic CPI-containing immunotherapy for unresectable or metastatic melanoma are allowed. Additional agents with CPI are permitted.
  • A maximum of one line of targeted therapy is allowed, and it must be the most recent .
  • Participants must have documented progressive disease as per RECIST v1.1 while on/after treatment with targeted therapy.

Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:

  • ≤ 4 weeks for radiation therapy or ≤ 2 weeks for limited field radiation for palliation prior to the first dose of study treatment.
  • ≤ 2 weeks for small molecule therapeutics.
  • ≤ 4 weeks for any immunotherapy treatment including .
  • ≤ 4 weeks for chemotherapy agents, locally directed anti-neoplastic agents, or other agents.
  • ≤ 6 weeks for cytotoxic agents with major delayed toxicities, such as nitrosourea and mitomycin c.

Participants participating in additional parallel investigational drug or medical device studies.

All primary central nervous system (CNS) tumors or symptomatic that are neurologically unstable History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).

Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Other protocol-defined exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    LXH254 + LTT462

    Drug: LXH254 · Drug: LTT462

  • Experimental
    LXH254 + trametinib

    Drug: Trametinib

  • Experimental
    LXH254 + ribociclib

    Drug: Ribociclib

Interventions

  • DrugNaporafenibStudies of NaporafenibNaporafenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    LXH254 will be supplied as tablet for oral use.

  • DrugLTT462

    LTT462 will be supplied as hard gelatin capsule for oral use.

  • Trametinib will be supplied as film-coated tablet for oral use

  • Ribociclib will be supplied in tablets and hard gelatin capsules.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Confirmed ORR using RECIST v1.1, per local assessment

    Time frame: 35 months

Secondary outcomes

  1. Duration of Reposnse (DOR)

    Local and central assessment

    Time frame: 4 years

  2. Progression Free Survival (PFS)

    Time frame: 4 years

  3. Disease Control Rate (DCR)

    Using RECIST v1.1, per local and central assessment

    Time frame: 3 years

  4. Overall Survival (OS)

    Time frame: 4 years

  5. Derived PK parameter (Cmax) for LXH254 & LTT462

    Time frame: Up to 5 months

  6. Derived PK parameter (Cmax) for LXH254 & trametinib

    Time frame: Up to 5 months

  7. Derived PK parameter (Cmax) for LXH254 & ribociclib

    Time frame: Up to 5 months

  8. Derived PK parameter (AUC) for LXH254 & LTT462

    Time frame: Up to 5 months

  9. Derived PK parameter (AUC) for LXH254 & trametinib

    Time frame: Up to 5 months

  10. Derived PK parameter (AUC) for LXH254 & ribociclib

    Time frame: Up to 5 months

  11. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with Adverse Events (AEs) and SAEs as a measure of safety and tolerability

    Time frame: 35 months

  12. Dose Interruptions

    Tolerability measured by the number of subjects who have interruptions of study treatment and reason for interruptions

    Time frame: 35 months

  13. Dose reductions

    Tolerability measured by the number of subjects who have reductions of study treatment and reason for reductions

    Time frame: 35 months

07

Study locations

36 sites
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • UCSF Medical Center
    San Francisco, California 94143, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic Mayo Rochester
    Rochester, Minnesota 55905, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • NYU Laura and Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering
    New York, New York 10017, United States
  • University of Pittsburgh Med Center
    Pittsburgh, Pennsylvania 15213, United States
  • Univ of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1426ANZ, Argentina
  • Novartis Investigative Site
    North Sydney, New South Wales 2060, Australia
  • Novartis Investigative Site
    Wooloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Subiaco, Western Australia 6008, Australia
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Wilrijk, 2610, Belgium
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Marseille, 13885, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Villejuif, 94800, France
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Maastricht, Limburg 6229 HX, Netherlands
  • Novartis Investigative Site
    Oslo, 0310, Norway
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Manchester, M20 2BX, United Kingdom
08

References and documents

Publications

  • Moschos SJ. War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging. Clin Cancer Res. 2022 Jul 15;28(14):2977-2979. doi: 10.1158/1078-0432.CCR-22-1256. PubMed 35587446 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Feb 2027, 75 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 75 months is above that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 4, 2020
StartActual
Oct 30, 2020
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04417621
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Oct 30, 2020
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Mar 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naporafenib · Trametinib

Start the discussion